SCHEMBL27432908

SCHEMBL27432908

CCCCCc1ccc(-c2ccc(C)cc2)nc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 12/20 0.73
▸ SMN1; SMN2 Q16637 11/20 0.73
▸ NPC1 O15118 10/20 0.73
▸ MAPT P10636 5/20 0.73
▸ ATM Q13315 2/20 0.73
▸ STAT3 P40763 1/20 0.73
▸ L3MBTL1 Q9Y468 2/20 0.71
▸ CASP3 P42574 2/20 0.71
▸ SENP8 Q96LD8 2/20 0.71
▸ SENP7 Q9BQF6 2/20 0.71
▸ SENP6 Q9GZR1 2/20 0.71
▸ NFKB1 P19838 4/20 0.68
▸ NFKB2 Q00653 4/20 0.68
▸ RELA Q04206 4/20 0.68
▸ MAPK1 P28482 2/20 0.68
▸ KDM4E B2RXH2 4/20 0.60
▸ ALDH1A1 P00352 4/20 0.60
▸ HPGD P15428 4/20 0.60
▸ TP53 P04637 3/20 0.57
▸ POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27432909 0.98 RAB9A (0.76) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL27432913 0.98 RAB9A (0.76) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL27432926 0.98 RAB9A (0.76) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL27432954 0.95 RAB9A (0.74) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL9620646 0.92 RAB9A (0.79) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL10556984 0.90 RAB9A (0.77) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL9620693 0.90 RAB9A (0.77) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL10558151 0.90 RAB9A (0.82) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL10556280 0.90 RAB9A (0.77) RAB9ASMN1; SMN2NPC1MAPTATM
SCHEMBL9839581 0.90 RAB9A (0.82) RAB9ASMN1; SMN2NPC1MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12022832-B2 Compounds and methods for treating nematode infections HNMT, NISCH, HRH2 RAB9A 2708/4885SMN1; SMN2 1819/4885NPC1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback